Answers are grounded in this paper and cite their sources.
Phase 3 study reports efficacy and safety of guselkumab in East Asian participants, indicating global consistency.
Efficacy and safety results of SC guselkumab in East Asian participants with moderately to severely active CD reflect findings from the global study.
No takes yet. Share an insight, caveat, or question.
Liu et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: